-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed Reports Neflamapimod Misses Primary Endpoint in Phase 2b Lewy Body Dementia Trial

PUBT·10/29/2026 11:41:20
CervoMed Reports Neflamapimod Misses Primary Endpoint in Phase 2b Lewy Body Dementia Trial
  • CervoMed announced publication of Phase 2b RewinD-LB results for neflamapimod in dementia with Lewy bodies in Alzheimer's Research & Therapy.
  • The 159-patient trial failed to confirm earlier benefits on its primary clinical outcome in the overall population.
  • Greater benefit emerged in patients without Alzheimer's co-pathology; higher drug exposure was associated with better outcomes.
  • A separate study published in Cells found neflamapimod inhibited inflammatory signaling implicated in cognitive decline, supporting further development.
  • Full results from the trial's 32-week extension are expected in a separate publication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290730PRIMZONEFULLFEED9855737) on October 29, 2026, and is solely responsible for the information contained therein.